Patient P-03293

Synthetic patientONX-7 · Day 134 · 75+ · F · baseline S14Open companion preview

Therapy response

Unstable

Tolerance

Deteriorating

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

78%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 ONX-7 started — Baseline state S14
Day 54 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 69 GI-04 recommended — GI Support Protocol GI-04
Day 70 Patient accepted — Started GI-04 in the companion
Day 78 No meaningful change — GI Support Protocol GI-04

What changed?

Trajectory began diverging from predicted response on Day 54.

Primary contributors, last 14 days

Toxicity+16
Treatment adherence+8
Inflammatory activity+5
GI instability-2

What helped?

GI Support Protocol GI-04Day 69
Result: no meaningful change

LIFE OS recommendation

Dosing / Timing Recommendation DT-01

70%

probability of meaningful tolerance improvement

284 similar trajectories
80% showed improvement
median effect visible after 5 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 61
Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 49
Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 27/100
- Daily logFibre intake low in recent food logs
Mucosal barrier integrity ↓50
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 70 and rising
Autonomic recovery ↑45
- WearableResting HR 79 bpm
- Wearable919 steps/day

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Poor metabolizer
Higher exposure at standard dose

Microbiome

Shannon diversity 2.1 · butyrate capacity 27/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 46 ms
Sleep: 6.6 h
Steps: 1,753
Resting HR: 76 bpm

Daily log: GI score 70, nutritional resilience 33, adherence 49.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-03323	49%	S14	GI-04	improved	48
P-03037	48%	S14	NP-02	improved	43
P-03049	47%	S14	GI-04	improved	49
P-03413	47%	S14	ME-01	improved	48
P-03390	46%	S14	ME-01	improved	41
P-03341	45%	S14	NP-02	improved	49
P-03430	45%	S14	SC-12	improved	45
P-03460	43%	S11	SC-12	improved	46
P-03345	42%	S14	SC-12	improved	56
P-03251	41%	S14	SC-12	improved	54
P-03123	40%	S14	GI-04	improved	50
P-03070	37%	S14	GI-04	improved	51